INCEPTA PHARMACEUTICALS LTD.DHAKA, BANGLADESH Company Profile Supervised by Professor Pares Chandra Mondale Department of Masters of Business Studies Jagannat University Bangladesh Submitted by Md. Golam Kibria ID No: MBS 560068 Department of Business Studies Jagannat University Bangladesh Feb 20, 2010. Professor Pares Chandra Mondale Department of Masters of Business Studies Jagannat University of Bangladesh Golam Kibria ID No: MBS 560068 Department of Business Studies Jagannat University Bangladesh . Three months works on this organization was a worthwhile experience for me as it was in such a reputed organization. _________________ Md. BANGLADESH Subject: Letter of Transmittal Sir. I am presenting my internship report “Financial Management of Pharmaceuticals Company: Study on Incepta Pharmaceuticals LTD I have collected as much information as possible from pharmaceuticals activities of the IPL. Sincerely Yours. DHAKA. It is a great pleasure for me to present you the report as a requirement of with the Masters of Business Administration.INCEPTA PHARMACEUTICALS LTD. I believe that this internship program has enriched both my knowledge and experience. Without his help. Special thanks go to Md. Human Resources Department. Who have helped me prepare this report successfully? (Md. for giving me the opportunity to fulfill my Internship program. Finance & Accounts Department. Executive Officer). He has guided me in coordinating the whole report. DHAKA. Ashhaduzzaman (Sr. Incepta Pharmaceuticals Ltd. assistance and encouragement of a number of individuals. Many of them played a decisive role in helping me writing this report.INCEPTA PHARMACEUTICALS LTD. Finance & Accounts Department and Syed Md. Assistant manager. I have been fortunate to have the support. Incepta Pharmaceuticals Ltd. BANGLADESH ACKNOWLEDGEMENT While preparing this report. Golam Kibria) ID No: MBS 560068 Major in Accounting Department of Masters of Business Studies (in Accounting) Jagannat University Bangladesh Company profile . My heartiest thanks and gratitude to Md. I convey my sincere thanks to all the individuals of Incepta Pharmaceuticals Ltd. Sultan Mahmood. I am very much grateful to my honorable advisor Professor Pares Chandra Mondale for assigning me to prepare this report. it would have been difficult to prepare the report. And finally. Zakir Khan (Assistant manager). Finance & Accounts. He has taken time to check the report and has given her suggestion on different portion of the report. Executive Officer). Mohammad Monwarul Islam (Sr. dry powder inhalers. The company produces various types of dosage forms which include tablets. coated pellets. Incepta intends to bring newer products of advanced technology through research hitherto unknown in this country. which promotes the specialties throughout the country. Incepta has quickly developed a very competent sales team. injection ampoules. Plans are underway to get into reverse engineering and analogue research in order to produce new API. 35 kilometer away from the center of the capital city Dhaka. It has established a modern research and development laboratory for the development of new advanced dosage forms for various drugs and devices like poorly soluble drugs. Established in the year 1999. oral liquids. Since its inception. Incepta has been launching new and innovative products in order to fulfill unmet demand of the medical community. The company has a very big manufacturing facility located at Savar. The products are of high standard and therefore these will be . the company’s commercial operation started in 2000. DHAKA. The company is now expanding its activities beyond the geographical boundary of Bangladesh. dry powder vials. The Research and Development department for various dosage forms has been very well developed. etc. cream/ointment. eye drops. BANGLADESH 1. capsules. nasal sprays. The company virtually covers every single corner of the rural as well as urban area of Bangladesh. powder for suspension. Such activities will not only benefit the company but also the total pharmaceutical sector of the country. barrier coated delayed release tablets etc. taste masked preparation etc. The focus was to bring more new technologically advanced molecules to this country. It has its own large distribution network having 14 depots all over the country. is a leading pharmaceutical company in Bangladesh. The company specializes in value added high technology dosage forms like sustained release tablets. The company also intends to embark into the production of Active Pharmaceutical Ingredient (API). quick mouth dissolving tablets. The company has a clear vision to become a leading research based dosage form manufacturing company with global presence within a short period of time.INCEPTA PHARMACEUTICALS LTD. ABOUT ORGANIZATION: Incepta Pharmaceuticals Ltd. modified release products. Zirabo. 2.com : www. Dhaka : +880-2-883 7811-26. Savar. The future is wide open and the opportunities are bountiful. Total number of employees Scientific & Technical Others 6.16 million USD • Telephone • Fax • E-mail • Website 3. Dhaka-1208. Incepta will continue to strive to provide high quality medicine at affordable prices to the people here in Bangladesh and other parts of the globe. Capital Value of Authorized capital Paid up capital/ Reserves 7. +880-2-8837946-49 : +880-2-8837952 : [email protected] ehsan@inceptapharma. Total Sales turnover in the previous four years-each year separately (split between Export and domestic) sale: . Bangladesh Factory: : Bara Rangamatia. BANGLADESH exported to both developed and developing countries. Shahid Tajuddin Ahmed Sharani. The company is open to collaborate with interested parties in various countries. Name of Company • Address : Incepta Pharmaceuticals Limited Head Office: : 40.50 million USD/ 4. Tejgaon Industrial Area.INCEPTA PHARMACEUTICALS LTD. Year of Establishment 4.00 million USD : 7. Form of Company 5. DHAKA.inceptapharma.com : 1999 : Private Limited : 3050 : 191 : 2859 : 16. 14. sachets. oral liquids and Injectables. Savar. 27.10 2006 24.14 2007 2428 41. It has its own manufacturing plant which is WHO-GMP compliant and certified with approval from international organizations. ointments. Zirabo.80 2005 26. Manufacturing facilities: Strength and capability of Incepta Pharmaceuticals Limited is now well established with strong quality image in Bangladesh pharmaceutical market.000 square feet area (approx. nasal sprays.32 USD) 8. Fax: +880-2-7708507 Total Floor Area of the Factory: General Production Area – Approx. Address of Factory: Dewan Idris Road. Cephalosporin group of products are manufactured in a completely separate building.6. BANGLADESH Year 2009 Export Sale (Thousand 3020 USD) Domestic Sale (Million 48. DHAKA.387 2008 27. capsules.58 2004 46.500 square meters) with state of the art manufacturing facilities.000 square meter) with a build-up total floor area of about 231. Dhaka. Savar about 35 kilometers from the capital city and is spread over the land of about 151.29 9. Recently the facility has got European “Certificate of GMP Compliance”. 9.400 square feet (approx. creams.14 2006 450 36.7 2007 17. Bara Rangamatia. spray dried specialized dosage forms etc.000 ft2 (2. The plant manufactures tablets.36 2008 3350 52.509 m2) * Hi-Tech Production Area – Approx. Telephone : +880-2-7708502 . powder for oral suspensions. Growth Rate (as %): Year Turnover 200 9 50.21. ophthalmic products. The pharmaceutical plant is located at Zirabo.INCEPTA PHARMACEUTICALS LTD.150 ft2 (850 m2) * .76 2005 30 2004 23. 70 Million/Year : 2.500 ft2 (1.000 ft2 (1.068) m2 * Administration – Approx.115 m2) * Equal amount of service floor area is available which is not shown here. BANGLADESH Cephalosporin Production Area – Approx.120 ft2 (1.26 Million Tubes/Year .320 ft2 (1. 22.80 Million Bottles/Year 0. The installed production capacities are – GENERAL PRODUCTS Tablets Capsules Liquid Injection ampoules Eye Drops Infusion Bags Infusion Bottles Liquid Injection Vials Dry Vial for Injection Nasal Spray Cream/Ointment.700 ft2 (2.57 Million Vials/Year 5. 17./Shampoo : : : : : : : : : 1920.110 m2) Utility & others – Approx.034 ft2 (1583 m2) Engineering – Approx.92 Million Bags/Year 0.810 m2) QA/QC – Approx.981 m2) * Warehouse – Approx.INCEPTA PHARMACEUTICALS LTD.60 Million/Year 2. 21.96 Million /Year 3.080 ft2 (844 m2) * Canteen.830 ft2 (821 m2) * R&D Formulation – Approx. 41.000 ft2 (3. 9. DHAKA. Laundry & others – Approx. 18. 15.684 m2) * Lyo Other Area – Approx.120 ft2 (1.00 Million/Year 120. 12.440 m2) * Lyo Production Area – Approx.00 Million/Year 24.684 m2) Liquid (New) Production Area – Approx. 11.00 Million/Year 1. 18. 8.500 ft2 (1. Iran. Germany. Sierra Leon. Jordan. Philippines. Pipeline country : Armenia. BANGLADESH Oral Liquids Sachet of Oral Powder Lyophilized vials Pre-filled Syringes : : : : 29. Pakistan.80 Million Bottles /Year 19. Malaysia. quality control and quality assurance. Belize. Congo. Mozambique. Azerbaijan. engineering etc. Ethiopia. Kuwait. Benin. Russia. Saudi Arabia. Vietnam. Turkey. Burkina Faso. Chile. Laos. Honduras. Sudan. Libya. Myanmar.80 Million /Year Powder for Oral Suspensions : CEPHALOSPORIN PRODUCTS Tablets Capsules Dry Vial for Injection : : : 90. Maldives. 10. Mongolia.00 Million/Year 76. Uganda and UAE. Costa Rica. Egypt. Tanzania. Ukraine. Burundi. Export: Existing Country: Afghanistan. Ghana. DHAKA.00 Million/Year 3. Mauritania. R&D Formulation. Moldova. Tajikistan. Togo.INCEPTA PHARMACEUTICALS LTD.80 Million /Year 1.00 Million/Year Powder for Oral Suspensions : The plant employs about 700 people and has manufacturing and warehousing facilities. Sri Lanka. Niger. Panama. Somalia. Bhutan. Thailand. Guyana. Hong Kong. Macau. South Africa. Georgia. El Salvador. Kenya. Mali. Ivory Coast. Indonesia. Austria.80 Million Sachets/Year 1. .24 Million Bottles /Year 6. Cambodia.48 Million Bottles/Year 3. Yemen. Dominican Republic. Bolivia. Kazakhstan. Canada. our position in the industry is currently 2nd in 2010 with the highest growth rate among the top 10 companies here in Bangladesh. Argentina. Position in Industry: According to IMS health survey. DHAKA. Singapore. USA. . Qatar. Trinidad & Tobago. Syria. Peru. Gabon. Zimbabwe 11.INCEPTA PHARMACEUTICALS LTD. Belarus. Brazil. BANGLADESH Future Plan: Algeria . Angola. Senegal. Morocco. Mexico. Turkmenistan.